Back to top

Immuneering publishes preclinical data on atebimetinib in Cancer Research

Immuneering (IMRX) announced the publication of new findings in Cancer Research, a journal of the American Association for Cancer Research, charact...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Immuneering Corporation (IMRX)